Answers are grounded in this paper and cite their sources.
) fivefold, enabling detection of F1P and its loss in models of HCC. In summary, we posit that in the liver, fructolysis to F1P is lost in the development of cancer and can be used as a biomarker of tissue function in the clinic using metabolic imaging.
No takes yet. Share an insight, caveat, or question.
Tee et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: